Association between carotid plaque vulnerability and high mobility group box-1 serum levels in a diabetic population.
Aged
Biomarkers
/ blood
C-Reactive Protein
/ analysis
Carotid Stenosis
/ blood
Case-Control Studies
Diabetes Mellitus, Type 2
/ blood
Female
HMGB1 Protein
/ blood
Humans
Inflammation Mediators
/ metabolism
Interleukin-6
/ blood
Italy
/ epidemiology
Male
Osteoprotegerin
/ blood
Plaque, Atherosclerotic
Prognosis
Risk Assessment
Risk Factors
Rupture, Spontaneous
Tumor Necrosis Factor-alpha
/ blood
Diabetes mellitus
High mobility group box-1 (HMGB1)
Internal carotid artery stenosis (ICAS)
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
27 05 2021
27 05 2021
Historique:
received:
25
03
2021
accepted:
19
05
2021
entrez:
28
5
2021
pubmed:
29
5
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Carotid atherosclerosis represents one of the complications of diabetes mellitus. In particular, plaque instability contributes to disease progression and stroke incidence. High mobility group box-1 (HMGB1) is a nuclear protein involved in promotion and progression of atherosclerosis and cardiovascular diseases. The aim of this study was to analyze the relationship between HMGB1 serum levels, main inflammatory cytokines, the presence of internal carotid stenosis and unstable plaque in a diabetic population. We studied 873 diabetic patients, including 347 patients with internal carotid artery stenosis (ICAS) who underwent carotid endarterectomy and 526 diabetic patients without internal carotid artery stenosis (WICAS). At baseline, HMGB1 and the main inflammatory cytokines serum levels were evaluated. For ICAS patients, the histological features of carotid plaque were also collected to differentiate them in patients with stable or unstable atherosclerotic lesions. We found that HMGB1 serum levels, osteoprotegerin, high-sensitivity C-reactive protein, tumor necrosis factor-alpha and interleukin-6, were significantly higher in diabetic ICAS patients compared to diabetic WICAS patients. Among ICAS patients, individuals with unstable plaque had higher levels of these cytokines, compared to patients with stable plaque. A multivariable stepwise logistic regression analysis showed that HMGB1 and osteoprotegerin remained independently associated with unstable plaque in ICAS patients. The present study demonstrated that HMGB1 is an independent risk factor for carotid plaque vulnerability in an Italian population with diabetes mellitus, representing a promising biomarker of carotid plaque instability and a possible molecular target to treat unstable carotid plaques and to prevent stroke.
Sections du résumé
BACKGROUND
Carotid atherosclerosis represents one of the complications of diabetes mellitus. In particular, plaque instability contributes to disease progression and stroke incidence. High mobility group box-1 (HMGB1) is a nuclear protein involved in promotion and progression of atherosclerosis and cardiovascular diseases. The aim of this study was to analyze the relationship between HMGB1 serum levels, main inflammatory cytokines, the presence of internal carotid stenosis and unstable plaque in a diabetic population.
RESEARCH DESIGN AND METHODS
We studied 873 diabetic patients, including 347 patients with internal carotid artery stenosis (ICAS) who underwent carotid endarterectomy and 526 diabetic patients without internal carotid artery stenosis (WICAS). At baseline, HMGB1 and the main inflammatory cytokines serum levels were evaluated. For ICAS patients, the histological features of carotid plaque were also collected to differentiate them in patients with stable or unstable atherosclerotic lesions.
RESULTS
We found that HMGB1 serum levels, osteoprotegerin, high-sensitivity C-reactive protein, tumor necrosis factor-alpha and interleukin-6, were significantly higher in diabetic ICAS patients compared to diabetic WICAS patients. Among ICAS patients, individuals with unstable plaque had higher levels of these cytokines, compared to patients with stable plaque. A multivariable stepwise logistic regression analysis showed that HMGB1 and osteoprotegerin remained independently associated with unstable plaque in ICAS patients.
CONCLUSIONS
The present study demonstrated that HMGB1 is an independent risk factor for carotid plaque vulnerability in an Italian population with diabetes mellitus, representing a promising biomarker of carotid plaque instability and a possible molecular target to treat unstable carotid plaques and to prevent stroke.
Identifiants
pubmed: 34044825
doi: 10.1186/s12933-021-01304-8
pii: 10.1186/s12933-021-01304-8
pmc: PMC8161555
doi:
Substances chimiques
Biomarkers
0
HMGB1 Protein
0
HMGB1 protein, human
0
IL6 protein, human
0
Inflammation Mediators
0
Interleukin-6
0
Osteoprotegerin
0
TNF protein, human
0
TNFRSF11B protein, human
0
Tumor Necrosis Factor-alpha
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
114Commentaires et corrections
Type : ErratumIn
Références
Johnson CO, Nguyen M, Roth GA, Nichols E, Alam T, Abate D, Abd-Allah F, Abdelalim A, Abraha HN, Abu-Rmeileh NM, Adebayo OM. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(5):439–58.
doi: 10.1016/S1474-4422(19)30034-1
Flaherty ML, Kissela B, Khoury JC, Alwell K, Moomaw CJ, Woo D, Khatri P, Ferioli S, Adeoye O, Broderick JP, et al. Carotid artery stenosis as a cause of stroke. Neuroepidemiology. 2013;40(1):36–41.
pubmed: 23075828
doi: 10.1159/000341410
Selwaness M, Bos D, van den Bouwhuijsen Q, Portegies ML, Ikram MA, Hofman A, Franco OH, van der Lugt A, Wentzel JJ, Vernooij MW. Carotid atherosclerotic plaque characteristics on magnetic resonance imaging relate with history of stroke and coronary heart disease. Stroke. 2016;47(6):1542–7.
pubmed: 27165952
doi: 10.1161/STROKEAHA.116.012923
Marnane M, Prendeville S, McDonnell C, Noone I, Barry M, Crowe M, Mulligan N, Kelly PJ. Plaque inflammation and unstable morphology are associated with early stroke recurrence in symptomatic carotid stenosis. Stroke. 2014;45(3):801–6.
pubmed: 24481971
doi: 10.1161/STROKEAHA.113.003657
Ammirati E, Moroni F, Norata GD, Magnoni M, Camici PG. Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis. Mediators Inflamm. 2015;2015:1–15.
doi: 10.1155/2015/718329
Schillinger M, Exner M, Mlekusch W, Sabeti S, Amighi J, Nikowitsch R, Timmel E, Kickinger B, Minar C, Pones M, et al. Inflammation and carotid artery-risk for atherosclerosis study (ICARAS). Circulation. 2005;111(17):2203–9.
pubmed: 15851593
doi: 10.1161/01.CIR.0000163569.97918.C0
Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the rotterdam study. Circulation. 2005;111(5):570–5.
pubmed: 15699277
doi: 10.1161/01.CIR.0000154553.12214.CD
Debing E, Peeters E, Demanet C, De Waele M, Van den Brande P. Markers of inflammation in patients with symptomatic and asymptomatic carotid artery stenosis: a case-control study. Vasc Endovascular Surg. 2008;42(2):122–7.
pubmed: 18421029
doi: 10.1177/1538574407307406
Eltoft A, Arntzen KA, Wilsgaard T, Mathiesen EB, Johnsen SH. Interleukin-6 is an independent predictor of progressive atherosclerosis in the carotid artery: the tromso study. Atherosclerosis. 2018;271:1–8.
pubmed: 29453087
doi: 10.1016/j.atherosclerosis.2018.02.005
Biscetti F, Straface G, Porreca CF, Bertoletti G, Vincenzoni C, Snider F, Stigliano E, Arena V, Angelini F, Pecorini G, et al. Increased FGF23 serum level is associated with unstable carotid plaque in type 2 diabetic subjects with internal carotid stenosis. Cardiovasc Diabetol. 2015;14:139.
pubmed: 26459301
pmcid: 4603970
doi: 10.1186/s12933-015-0301-5
Flex A, Biscetti F, Iachininoto MG, Nuzzolo ER, Orlando N, Capodimonti S, Angelini F, Valentini CG, Bianchi M, Larocca LM, et al. Human cord blood endothelial progenitors promote post-ischemic angiogenesis in immunocompetent mouse model. Thromb Res. 2016;141:106–11.
pubmed: 26994683
doi: 10.1016/j.thromres.2016.03.012
Pola R, Flex A, Ciaburri M, Rovella E, Valiani A, Reali G, Silveri MC, Bernabei R. Responsiveness to cholinesterase inhibitors in alzheimer’s disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene. Neurosci Lett. 2005;382(3):338–41.
pubmed: 15925115
doi: 10.1016/j.neulet.2005.03.027
Malarkey CS, Churchill MEA. The high mobility group box: the ultimate utility player of a cell. Trends Biochem Sci. 2012;37(12):553–62.
pubmed: 23153957
pmcid: 4437563
doi: 10.1016/j.tibs.2012.09.003
Biscetti F, Rando MM, Nardella E, Cecchini AL, Pecorini G, Landolfi R, Flex A. High mobility group box-1 and diabetes mellitus complications: state of the art and future perspectives. Int J Mol Sci. 2019;20:6258.
pmcid: 6940913
doi: 10.3390/ijms20246258
pubmed: 6940913
Biscetti F, Straface G, De Cristofaro R, Lancellotti S, Rizzo P, Arena V, Stigliano E, Pecorini G, Egashira K, De Angelis G, et al. High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes. 2010;59(6):1496–505.
pubmed: 20200317
pmcid: 2874711
doi: 10.2337/db09-1507
Kalinina N, Agrotis A, Antropova Y, DiVitto G, Kanellakis P, Kostolias G, Ilyinskaya O, Tararak E, Bobik A. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol. 2004;24(12):2320–5.
pubmed: 15374849
doi: 10.1161/01.ATV.0000145573.36113.8a
Benlier N, Erdoğan MB, Keçioğlu S, Orhan N, Çiçek H. Association of high mobility group box 1 protein with coronary artery disease. Asian Cardiovasc Thorac Ann. 2019;27(4):251–5.
pubmed: 30818961
doi: 10.1177/0218492319835725
Gao W, Cui H, Li Q, Zhong H, Yu J, Li P, He X. Upregulation of microRNA-218 reduces cardiac microvascular endothelial cells injury induced by coronary artery disease through the inhibition of HMGB1. J Cell Physiol. 2020;235(3):3079–95.
pubmed: 31566720
doi: 10.1002/jcp.29214
Andrassy M, Volz HC, Riedle N, Gitsioudis G, Seidel C, Laohachewin D, Zankl AR, Kaya Z, Bierhaus A, Giannitsis E, et al. HMGB1 as a predictor of infarct transmurality and functional recovery in patients with myocardial infarction. J Intern Med. 2011;270(3):245–53.
pubmed: 21362071
doi: 10.1111/j.1365-2796.2011.02369.x
Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, Buss S, Autschbach F, Pleger ST, Lukic IK, et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation. 2008;117(25):3216–26.
pubmed: 18574060
doi: 10.1161/CIRCULATIONAHA.108.769331
Kanellakis P, Agrotis A, Kyaw TS, Koulis C, Ahrens I, Mori S, Takahashi HK, Liu K, Peter K, Nishibori M, et al. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2011;31(2):313–9.
pubmed: 21088249
doi: 10.1161/ATVBAHA.110.218669
Andrassy M, Volz HC, Maack B, Schuessler A, Gitsioudis G, Hofmann N, Laohachewin D, Wienbrandt AR, Kaya Z, Bierhaus A, et al. HMGB1 is associated with atherosclerotic plaque composition and burden in patients with stable coronary artery disease. PLoS ONE. 2012;7(12):e52081.
pubmed: 23284878
pmcid: 3524090
doi: 10.1371/journal.pone.0052081
Hu X, Jiang H, Bai Q, Zhou X, Xu C, Lu Z, Cui B, Wen H. Increased serum HMGB1 is related to the severity of coronary artery stenosis. Clin Chim Acta. 2009;406(1–2):139–42.
pubmed: 19545550
doi: 10.1016/j.cca.2009.06.016
Giovannini S, Tinelli G, Biscetti F, Straface G, Angelini F, Pitocco D, Mucci L, Landolfi R, Flex A. Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects. Cardiovasc Diabetol. 2017;16(1):99.
pubmed: 28789654
pmcid: 5549317
doi: 10.1186/s12933-017-0581-z
Inoue K, Kawahara K, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M, Maruyama I. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol. 2007;16(3):136–43.
pubmed: 17502242
doi: 10.1016/j.carpath.2006.11.006
Biscetti F, Straface G, Porreca CF, Bertoletti G, Vincenzoni C, Snider F, Stigliano E, Arena V, Angelini F, Pecorini G, et al. Increased FGF23 serum level is associated with unstable carotid plaque in type 2 diabetic subjects with internal carotid stenosis. Cardiovasc Diabetol. 2015. https://doi.org/10.1186/s12933-015-0301-5 .
doi: 10.1186/s12933-015-0301-5
pubmed: 26459301
pmcid: 4603970
Biscetti F, Bonadia N, Santini F, Angelini F, Nardella E, Pitocco D, Santoliquido A, Filipponi M, Landolfi R, Flex A. Sortilin levels are associated with peripheral arterial disease in type 2 diabetic subjects. Cardiovasc Diabetol. 2019;18(1):5.
pubmed: 30634965
pmcid: 6329108
doi: 10.1186/s12933-019-0805-5
Biscetti F, Nardella E, Bonadia N, Angelini F, Pitocco D, Santoliquido A, Filipponi M, Landolfi R, Flex A. Association between plasma omentin-1 levels in type 2 diabetic patients and peripheral artery disease. Cardiovasc Diabetol. 2019;18(1):74.
pubmed: 31167666
pmcid: 6549359
doi: 10.1186/s12933-019-0880-7
Biscetti F, Porreca CF, Bertucci F, Straface G, Santoliquido A, Tondi P, Angelini F, Pitocco D, Santoro L, Gasbarrini A, et al. TNFRSF11B gene polymorphisms increased risk of peripheral arterial occlusive disease and critical limb ischemia in patients with type 2 diabetes. Acta Diabetol. 2014;51(6):1025–32.
pubmed: 25323324
doi: 10.1007/s00592-014-0664-1
Biscetti F, Nardella E, Rando MM, Cecchini AL, Angelini F, Cina A, Iezzi R, Filipponi M, Santoliquido A, Pitocco D, et al. Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study. Cardiovasc Diabetol. 2020;19(1):170.
pubmed: 33028322
pmcid: 7542958
doi: 10.1186/s12933-020-01151-z
Biscetti F, Nardella E, Rando MM, Cecchini AL, Bonadia N, Bruno P, Angelini F, Di Stasi C, Contegiacomo A, Santoliquido A, et al. Sortilin levels correlate with major cardiovascular events of diabetic patients with peripheral artery disease following revascularization: a prospective study. Cardiovasc Diabetol. 2020;19(1):147.
pubmed: 32977814
pmcid: 7519536
doi: 10.1186/s12933-020-01123-3
Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol. 1995;15(9):1512–31.
pubmed: 7670967
doi: 10.1161/01.ATV.15.9.1512
Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20(5):1262–75.
pubmed: 10807742
doi: 10.1161/01.ATV.20.5.1262
Wu H, Chen Z, Xie J, Kang L-N, Wang L, Xu B. High mobility group box-1: a missing link between diabetes and its complications. Mediators Inflamm. 2016;2016:3896147.
pubmed: 27847406
pmcid: 5099456
Chen Q, Wang ZY, Chen LY, Hu HY. Roles of high mobility group box 1 in cardiovascular calcification. Cell Physiol Biochem. 2017;42(2):427–40.
pubmed: 28571029
doi: 10.1159/000477591
Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Muller S, Iannacone M, Traversari C, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 2004;5(8):825–30.
pubmed: 15272298
pmcid: 1299116
doi: 10.1038/sj.embor.7400205
Raggi P, Genest J, Giles JT, Rayner KJ, Dwivedi G, Beanlands RS, Gupta M. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis. 2018;276:98–108.
pubmed: 30055326
doi: 10.1016/j.atherosclerosis.2018.07.014
Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med. 2015;278(5):483–93.
pubmed: 26260307
pmcid: 5082111
doi: 10.1111/joim.12406
Wang R, Wu W, Li W, Huang S, Li Z, Liu R, Shan Z, Zhang C, Wang S. Activation of NLRP3 inflammasome promotes foam cell formation in vascular smooth muscle cells and atherogenesis via HMGB1. J Am Heart Assoc. 2018;7(19):e008596.
pubmed: 30371306
pmcid: 6404867
doi: 10.1161/JAHA.118.008596
Porto A, Palumbo R, Pieroni M, Aprigliano G, Chiesa R, Sanvito F, Maseri A, Bianchi ME. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. Faseb J. 2006;20(14):2565–6.
pubmed: 17060403
doi: 10.1096/fj.06-5867fje
Bentzon JF, Sondergaard CS, Kassem M, Falk E. Smooth muscle cells healing atherosclerotic plaque disruptions are of local, not blood, origin in apolipoprotein E knockout mice. Circulation. 2007;116(18):2053–61.
pubmed: 17938286
doi: 10.1161/CIRCULATIONAHA.107.722355
Chen J, Zhang J, Xu L, Xu C, Chen S, Yang J, Jiang H. Inhibition of neointimal hyperplasia in the rat carotid artery injury model by a HMGB1 inhibitor. Atherosclerosis. 2012;224(2):332–9.
pubmed: 22857898
doi: 10.1016/j.atherosclerosis.2012.07.020
Chang KC. Cilostazol inhibits HMGB1 release in LPS-activated RAW 264.7 cells and increases the survival of septic mice. Thromb Res. 2015;136(2):456–64.
pubmed: 26116490
doi: 10.1016/j.thromres.2015.06.017
Biscetti F, Pecorini G, Arena V, Stigliano E, Angelini F, Ghirlanda G, Ferraccioli G, Flex A. Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPARγ. Mol Cell Endocrinol. 2013;381(1–2):80–7.
pubmed: 23891623
doi: 10.1016/j.mce.2013.07.011
Biscetti F, Pecorini G, Straface G, Arena V, Stigliano E, Rutella S, Locatelli F, Angelini F, Ghirlanda G, Flex A. Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. Int J Cardiol. 2013;167(3):910–6.
pubmed: 22473072
doi: 10.1016/j.ijcard.2012.03.103
Biscetti F, Straface G, Bertoletti G, Vincenzoni C, Snider F, Arena V, Landolfi R, Flex A. Identification of a potential proinflammatory genetic profile influencing carotid plaque vulnerability. J Vasc Surg. 2015;61(2):374–81.
pubmed: 25441669
doi: 10.1016/j.jvs.2014.08.113
Biscetti F, Ghirlanda G, Flex A. Therapeutic potential of high mobility group box-1 in ischemic injury and tissue regeneration. Curr Vasc Pharmacol. 2011;9(6):677–81.
pubmed: 21692740
doi: 10.2174/157016111797484125
Biscetti F, Gentileschi S, Bertucci F, Servillo M, Arena V, Angelini F, Stigliano E, Bonanno G, Scambia G, Sacchetti B, et al. The angiogenic properties of human adipose-derived stem cells (HASCs) are modulated by the high mobility group box protein 1 (HMGB1). Int J Cardiol. 2017;249:349–56.
pubmed: 28967436
doi: 10.1016/j.ijcard.2017.09.165